The struggling pharmaceutical giant is showing signs of life.
Over the past 18 months, Merck (MRK +0.20%) shares have faced significant challenges, primarily due to various headwinds impacting performance. The vaccine business has underperformed, leading to lower-than-expected revenue growth. Moreover, a rising number of mid- and late-stage clinical candidates present potential threats to the market dominance of Keytruda, Merck’s blockbuster cancer drug. These factors have contributed to a decline in stock performance, raising concerns among investors.
Nonetheless, Merck has been diligently working to overcome these challenges. Recent developments have positively impacted the company’s prospects and share price, instilling a renewed sense of optimism. Let’s explore what these developments entail and their implications for potential investors.
Merck Achieves a Significant Mid-Stage Victory
In 2021, Merck made a strategic move by acquiring Acceleron Pharma, a smaller biotechnology company, for an impressive $11.5 billion. The key asset from this acquisition was sotatercept, which was under investigation as a treatment for pulmonary hypertension (PH), a serious condition characterized by high blood pressure in the lungs.
Since its acquisition, sotatercept has received regulatory approval and is now marketed under the brand name Winrevair. It is specifically indicated for treating a type of PH known as pulmonary arterial hypertension (PAH), which occurs when blood flow in the lungs is obstructed due to narrowed blood vessels. Winrevair has shown promising results, generating approximately $976 million in revenue within the first nine months of 2025 alone.
Image source: Getty Images.
Looking ahead, additional developments for sotatercept are promising. Merck recently shared that sotatercept has successfully completed a phase 2 study involving patients with combined post- and precapillary pulmonary hypertension (CpcPH) related to heart failure with preserved ejection fraction (HFpEF). Essentially, this condition arises when patients experience two causes of PH simultaneously, representing a subset of Group 2 PH, which is one of the more prevalent forms of the disease.
This mid-stage victory is crucial for Merck. Although CpcPH due to HFpEF is classified as rare, it is often underdiagnosed, with no specific treatments currently approved for it. Thus, Merck is strategically targeting a niche market where it may not face intense competition if sotatercept successfully navigates phase 3 studies and secures the necessary label expansion.
Even though the patient population is around 100,000 individuals, which aligns with the definition of “rare,” the potential for significant success in this indication is substantial. Analysts estimate that this could enhance the annual sales potential of sotatercept by over $1 billion. Consequently, Merck’s stock experienced a surge following this news, indicating investor confidence. While competition may arise, whether from biosimilars or other sources, the progress of sotatercept demonstrates promising potential for Merck to maintain its competitive edge.
Additional Positive Developments for Merck
Several other favorable developments further enhance Merck’s outlook. Let’s explore two noteworthy advancements.
Firstly, Merck has announced its intention to acquire Cidara Therapeutics (CDTX +0.06%), a mid-cap biotech company, for approximately $9.2 billion in cash. This acquisition will provide Merck access to CD388, a potential therapy that has the capacity to disrupt the influenza vaccine market. Existing flu vaccines have significant limitations, including reduced efficacy over the course of the season and diminished effectiveness in vulnerable populations such as the elderly and immunocompromised individuals.
CD388 aims to address these critical shortcomings. It has shown promising results in phase 2 studies and could emerge as a vital addition to Merck’s expanding portfolio, further solidifying its position in the market.
Today’s Change
(0.20%) $0.21
Current Price
$104.84
Key Data Points
Market Cap
$260B
Day’s Range
$104.13 – $105.41
52wk Range
$73.31 – $105.84
Volume
229K
Avg Vol
13M
Gross Margin
75.81%
Dividend Yield
3.09%
Secondly, Merck is nearing another exciting launch. The company is currently studying a combination of doravirine and islatravir for the treatment of HIV and is awaiting approval from the U.S. Food and Drug Administration, which is expected to occur early next year. This product could play a significant role in Merck’s strategy following the anticipated peak of Keytruda sales.
Additionally, it is noteworthy that Merck has recently received approval for a subcutaneous version of Keytruda. While this new formulation does not encompass all the indications of the original version, it will help mitigate the risks associated with an impending patent cliff. As Merck integrates the subcutaneous Keytruda with innovative products like Winrevair, its forthcoming HIV treatment, and Capvaxive—a pneumonia vaccine that received approval last year and generated $244 million in sales during the third quarter—it is well-positioned to navigate the challenges facing its core franchise.
Should You Consider Investing in Merck Stock?
As Merck continues to face challenges related to its vaccine business, the drugmaker is demonstrating resilience by showcasing its historical performance. The company’s robust pipeline and keen ability to identify promising opportunities suggest that it is likely to thrive over the long term, despite the obstacles it faces.
Moreover, Merck stands out as a strong dividend stock, having increased its payouts by an impressive 84.7% over the past decade, currently offering a forward yield of 3.5%. While it may not be the go-to stock for explosive growth, Merck is an excellent, reliable blue-chip income stock that deserves a place in any well-rounded investment portfolio.
